HERCe investigators have studied many different topics and health issues during the years. To help highlight the great work done by these investigators, we will periodically acknowledge their contributions and recent publications on this page.
Dr. Bob Wallace has been a stalwart presence in the world of Epidemiology for nearly five decades. His work in research and mentor ship has helped guide public health and the researchers of today. Recently deciding to transition to Professor Emeritus, we want to shine the spotlight on him and his amazing work. Click on the link below to reach more about his career and see videos and pictures from the Symposium held in his honor.
The first person to get this spotlight is Eric Ammann, a recent graduate from the College of Public Health and the newest investigator to join the HERCe group. His main focus has been on the Thromboembolic Events After Immunoglobulin Administration project through the FDA Mini-Sentinel. Eric’s work on this project has has been to study intravenous immune globulin (IVIg) use and its effect on thromboembolic adverse events (TEE) such as ischemic stroke, acute myocardial infarction, deep vein thrombosis and pulmonary embolism. In addition to his FDA-sponsored work, Eric’s dissertation research has resulted in two significant publications on this topic. The first identified a transient increase in arterial TEEs after IVIg in a retrospective cohort of Medicare beneficiaries with hypogammablobulinemia secondary to chronic lymphocytic leukemia or multiple myeloma. His second publication was a meta-analysis of adverse event data in randomized clinical trials of IVIg use from 1995 to 2015. In the meta-analysis, no evidence was found of increased TEE risk among IVIg treated patients compared with control patients but the trials reflected investigations for newer therapy indications and may not have represented standard uses. We look forward to working with Erin in the future, and thank him for his hard work and dedication to epidemiological research.